Source: http://www.asmscience.org/content/book/10.1128/9781555817794.chap23
Timestamp: 2019-04-26 05:50:14+00:00

Document:
Chemical structures of the first-generation quinolones (structure 1), nalidixic acid (structure 2), cinoxacin (structure 3), and pipemidic acid (structure 4).
Chemical structures of second-generation quinolones.
Chemical structures of thirdgeneration quinolones.
A typical phone cord is coiled like a DNA helix, and the coiled cord can itself coil into a supercoil. Reprinted from D. L. Nelson and M. M. Cox, Lehninger Principles of Biochemistry, 3rd ed. (Worth Publishers, New York, N.Y., 2000), with permission from the publisher.
Mechanism of the E. coli topoisomerase I reaction. This enzyme is not essential and is not inhibited by quinolones.
Cooperative quinolone–DNA-binding model for DNA gyrase inhibition proposed by Shen et al. (1989). See the text for details. Reprinted from I. Morrissey, K. Hoshino, K. Sato, A. Yoshida, I. Hayakawa, M. G. Bures, and L. L. Shen, Antimicrob. Agents Chemother.40:1775–1784, 1996, with permission from the American Society for Microbiology.
The model represented in Fig. 23.6 is further depicted by a brickstacking schematic presentation, with the symbols explained in the lower panel. Reprinted from I. Morrissey, K. Hoshino, K. Sato, A. Yoshida, I. Hayakawa, M. G. Bures, and L. L. Shen, Antimicrob. Agents Chemother. 40:1775–1784, 1996, with permission from the American Society for Microbiology.
Functional domains of quinolone antibacterial agents.
1. Andriole, V. T. (ed.). 2000. The Quinolones, 3rd ed. Academic Press, Inc., San Diego, Calif.
2. Hooper, D. C.,, and E. Rubinstein (ed). Quinolone Antimicrobial Agents, 3rd ed., in press. ASM Press, Washington, D.C.
3. Appelbaum, P. C.,, and P. A. Hunter. 2000. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 16: 5– 15.
4. Lesher, G. Y.,, E. D. Forelich,, M. D. Gruet,, J. H. Bailey,, and R. P. Brundage. 1962. 1,8-Naphthyridone derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 5: 1063– 1068.
5. Anderson, V. E.,, T. D. Gootz,, and N. Osheroff. 1998. Topoisomerase IV catalysis and the mechanism of quinolone action. J. Biol. Chem. 273: 17879– 17885.
6. Anderson, V. E.,, R. P. Zaniewski,, F. S. Kaczmarek,, T. D. Gootz,, and N. Osheroff. 2000. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry 39: 2726– 2732.
7. Drlica, K. 1999. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2: 504– 508.
8. Drlica, K.,, and X. Zhao. 1999. DNA topoisomerase IV as a quinolone target. Curr. Opin. Anti-Infect. Investig. Drugs 1: 435– 442.
9. Heddle, J.,, and A. Maxwell. 2002. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob. Agents Chemother. 46: 1805– 1815.
10. Hiasa, H.,, M. E. Shea,, C. M. Richardson,, and M. N. Gwynn. 2003. Staphylococcus aureus gyrase-quinolone-DNA tertiary complexes fail to arrest replication fork progression in vitro. J. Biol. Chem. 278: 8861– 8868.
11. Hooper, D. C. 1995. Quinolone mode of action. Drugs 49( Suppl. 2): 10– 15.
12. Kampranis, S.,, and A. Maxwell. 1998. Conformational changes in DNA gyrase revealed by limited proteolysis. J. Biol. Chem. 273: 22606– 22614.
13. Khodursky, A. B.,, and N. R. Cozzarelli. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273: 27668– 27677.
14. Marians, K. J.,, and H. Hiasa. 1997. Mechanism of quinolone action. J. Biol. Chem. 272: 9401– 9409.
15. Morrissey, I.,, and J. George. 1999. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerase purified as recombinant proteins. Antimicrob. Agents Chemother. 41: 2579– 2585.
16. Morrissey, I.,, K. Hoshino,, K. Sato,, A. Yoshida,, I. Hayakawa,, M. G. Bures,, and L. L. Shen. 1996. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents Chemother. 40: 1775– 1784.
17. Noble, C. G.,, F. M. Barnard,, and A. Maxwell. 2003. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase- DNA complex. Antimicrob. Agents Chemother. 47: 854– 862.
18. Shen, L. L.,, and A. G. Pernet. 1985. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drug is DNA. Proc. Natl. Acad. Sci. USA 82: 307– 311.
19. Bowater, R. P. Supercoiled DNA: structure. Accepted for publication in Encyclopedia of Life Sciences. Nature Publishing, London, United Kingdom. [Online.] http://www.els.net.
20. Nelson, D. L.,, and M. M. Cox. 2000. Lehninger Principles of Biochemistry, 3rd ed. Worth Publishers, New York, N.Y.
21. Adams, D. E.,, E. M. Shekhtman,, E. L. Zechiedrich,, M. B. Schmid,, and N. R. Cozzarelli. 1992. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 71: 277– 288.
22. Bates, A. D. Topoisomerases. Accepted for publication in Encyclopedia of Life Sciences. Nature Publishing, London, United Kingdom. [Online.] http://www.els.net.
23. Drlica, K.,, and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61: 377– 392.
24. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin. Infect. Dis. 27( Suppl. 1): S54– S63.
25. Hoshino, K.,, A. Kitamura,, I. Morrissey,, K. Sato,, J. Kato,, and H. Ikeda. 1994. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38: 2623– 2627.
26. Kato, J.,, Y. Nishimura,, R. Imamura,, H. Niki,, S. Hiraga,, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in E. coli. Cell 63: 393– 404.
27. Kato, J.,, H. Suzuki,, and H. Ikeda. 1992. Purification and characterization of DNA topoisomerase IV in Escherichia coli. J. Biol. Chem. 267: 25676– 25684.
28. Levine, C.,, H. Hiasa,, and K. J. Marians. 1998. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochem. Biophys. Acta 1400: 29– 43.
29. Luttinger, A. 1995. The twisted “life” of DNA in the cell: bacterial topoisomerases. Mol. Microbiol. 15: 601– 606.
30. Wang, J. C. 1996. DNA topoisomerases. Annu. Rev. Biochem. 65: 635– 692.
31. Critchlow, S. E.,, and A. Maxwell. 1996. DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry 35: 7387– 7393.
32. Kampranis, S.,, and A. Maxwell. 1998. The DNA gyrasequinolone complex. J. Biol. Chem. 273: 22615– 22626.
33. Morrissey, I.,, K. Hoshino,, K. Sato,, A. Yoshida,, I. Hayakawa,, M. G. Bures,, and L. L. Shen. 1996. Mechanism of differential activities of ofloxacin enantiomers. Antimicrob. Agents Chemother. 40: 1775– 1784.
34. Shen, L. L., 1993. Quinolone-DNA interaction, p. 77– 95. In D. C. Hooper, and J. S. Wolfson (ed.), Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, D.C.
35. Shen, L. L.,, J. Baranowski,, and A. G. Pernet. 1989. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 28: 3879– 3885.
36. Shen, L. L.,, W. E. Kohlbrenner,, D. Weigl,, and J. Baranowski. 1989. Mechanism of quinolone inhibition of DNA gyrase. J. Biol. Chem. 264: 2973– 2978.
37. Shen, L. L.,, L. A. Mitscher,, P. N. Sharma,, T. J. O’Donnell,, D. W. T. Chu,, C. S. Cooper,, T. Rosen,, and A. G. Pernet. 1989. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28: 3886– 3894.
38. Willmott, C. J. R.,, S. E. Critchlow,, I. C. Eperon,, and A. Maxwell. 1994. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. Mol. Biol. 242: 351– 363.
39. Berger, J. M.,, S. J. Gamblin,, S. C. Harrison,, and J. C. Wang. 1996. Structure at 2.7 Å resolution of a 92K yeast DNA topoisomerase II fragment. Nature 379: 225– 232.
40. Morais Cabral, J. H.,, A. P. Jackson,, C. V. Smith,, N. Shikotra,, A. Maxwell,, and R. C. Liddington. 1997. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388: 903– 906.
41. Wigley, D. B.,, G. J. Davies,, E. J. Dodson,, A. Maxwell,, and G. Dodson. 1991. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351: 624– 629.
42. Chu, D. T. W.,, and P. B. Fernandes. 1989. Structure-activity relationships of the fluoroquinolones. Antimicrob. Agents Chemother. 33: 438– 442.
43. Domagala, J. M. 1994. Structure-activity and structure-sideeffect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33: 685– 706.
44. Mitscher, L. A.,, P. Devasthale,, and R. Zavod,. 1993. Structureactivity relationships, p. 3– 51. In D. C. Hooper, and J. S. Wolfson (ed.), Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, D.C.
45. Chapman, J. S.,, and N. H. Georgopapadakou. 1988. Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother. 32: 131– 135.
46. Andriole, V. T. (ed.). 2000. The Quinolones, 3rd ed., Academic Press, Inc., San Diego, Calif.
47. Bryskier, A. 1999. Respiratory fluoroquinolones: myth or reality? Curr. Opin. Anti-Infect. Investig. Drugs 1: 413– 427.
48. Hooper, D. C. 2000. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30: 243– 254.
49. Kucers, A.,, S. M. Crowe,, M. L. Grayson,, and J. F. Hoy. 1997. The Use of Antibiotics. Butterworth-Heinemann, Oxford, United Kingdom.
50. Piddock, L. J. V. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38: 163– 169.
51. Acar, J. F.,, and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24( Suppl.1): S67– S73.
52. Hooper, D. C. 1999. Mechanism of fluoroquinolone resistance. Drug Resist. Updates 2: 38– 55.
53. Piddock, L. J. V. 1995. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 49( Suppl. 2): 29– 35.
54. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob. Agents Chemother. 44: 2233– 2241.
55. Sun, L.,, S. Sreedharan,, K. Plummer,, and L. M. Fisher. 1996. NorA plasmid resistance to fluoroquinolones:role of copy number and norA frameshift mutations. Antimicrob. Agents Chemother. 40: 1665– 1669.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.